ICLUSIG
13 218,33 R$
Max. consumer price (CMED)
Analogs of ICLUSIG
Find cheaper analogs and generic equivalents for ICLUSIG.
ਸਰਗਰਮ ਤੱਤ: ponatinib hydrochloride
ਉਤਪਾਦ ਝਲਕ
About ICLUSIG
ICLUSIG is a medication containing the active ingredient ponatinib hydrochloride, classified as Medication. Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor.
Key Benefits & Uses
- Used for: 1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic.
- Use only as directed on the product label or by a healthcare professional.
- Follow the authorised product information for dosing and duration of use.
Active Ingredient & Action
ponatinib hydrochloride, the active ingredient in ICLUSIG, belongs to the Medication class. 1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. Inactive ingredients: not listed in source data.
Important Notes
Always read and follow the label instructions carefully before taking ICLUSIG. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use ICLUSIG for extended periods without medical advice.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.